Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGENUS INCAGEN · Entity 5774 | VP and General Counsel | December 17, 2020 | December 21, 2020 |
| Cogent Biosciences, Inc.COGT · Entity 3793 | Chief Legal Officer | December 26, 2025 | December 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGENUS INC
Report date December 17, 2020 · Filed December 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2030-12-17 | Direct | 150,000 |
Reported balance
After 2020-12-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-17 · Grant · Acquired 150,000 · Balance 150,000 F1: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. One-third of the Stock Option vests on December 17, 2021, with the remaining vesting in eight equal quarterly installments thereafter (provided Mr. Kearns maintains a service relationship with the Company through each such vesting date). |
Filing footnotes · ownership attribution and instrument terms
F1: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. One-third of the Stock Option vests on December 17, 2021, with the remaining vesting in eight equal quarterly installments thereafter (provided Mr. Kearns maintains a service relationship with the Company through each such vesting date).
Cogent Biosciences, Inc.
Report date December 26, 2025 · Filed December 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,398 |
Reported balance
After 2025-12-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-26 · Sale · Disposed 65,000 · Balance 109,398 F1: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.52 to $38.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.52 to $38.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 26, 2025 Filed Dec 30, 2025 16:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | SaleCommon Stock | 65,000 | $38.70 | $2,515,500.00 |
DisclosureSEC source: 0001193125-25-337052 · ownership.xml · nonDerivative · entry 1 Kearns Evan · CIK 0001745285 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,398 F1 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.52 to $38.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 16:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $39.45 | $0.00 |
DisclosureSEC source: 0001193125-25-326772 · ownership.xml · derivative · entry 4 Kearns Evan · CIK 0001745285 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-12-17 F5 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 16:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | Tax withholdingCommon Stock | 125,602 | $39.45 | $4,954,998.90 |
DisclosureSEC source: 0001193125-25-326772 · ownership.xml · nonDerivative · entry 3 Kearns Evan · CIK 0001745285 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,398 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 16:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 260,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-326772 · ownership.xml · nonDerivative · entry 2 Kearns Evan · CIK 0001745285 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F2 · shares: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs"). Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 16:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-326772 · ownership.xml · nonDerivative · entry 1 Kearns Evan · CIK 0001745285 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 16:55 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 230,000 | $0.00 Strike: $8.89 | $0.00 |
DisclosureSEC source: 0000950170-25-009256 · ownership.xml · derivative · entry 1 Kearns Evan · CIK 0001745285 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2035-01-23 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:27 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 255,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000950170-24-007422 · ownership.xml · derivative · entry 1 Kearns Evan · CIK 0001745285 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 255,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 15:51 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0000899243-23-005140 · doc4.xml · derivative · entry 1 Kearns Evan · CIK 0001745285 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2033-02-13 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 17:42 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 202,250 | $4.94 Strike: $7.60 | $999,762.20 |
DisclosureSEC source: 0000899243-22-003469 · doc4.xml · derivative · entry 1 Kearns Evan · CIK 0001745285 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,250 Underlying: Common Stock · 202,250 shares Expires 2032-01-25 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| May 03, 2021 Filed May 5, 2021 16:37 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0000899243-21-018362 · doc4.xml · derivative · entry 1 Kearns Evan · CIK 0001745285 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2031-05-03 F1 · derivative.exercise_date: This stock option shall vest over a four year period as follows: 1/4th of the option shall vest one year after the vesting start date; then 1/48th of the option shall vest monthly over the remaining three year period. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 18:42 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option (Right to buy) · Derivative | 150,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001745285-20-000045 · primary_doc.xml · derivative · entry 1 Kearns Evan · CIK 0001745285 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-12-17 F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. One-third of the Stock Option vests on December 17, 2021, with the remaining vesting in eight equal quarterly installments thereafter (provided Mr. Kearns maintains a service relationship with the Company through each such vesting date). Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 20:34 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option (Right to buy) · Derivative | 300,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0000899243-19-030103 · doc4.xml · derivative · entry 1 Kearns Evan · CIK 0001745285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-12-24 F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. Option vests over a three-year period, with 1/3 of Option vesting on December 24, 2020, and the balance vesting in equal quarterly installments thereafter. Read SEC document |
| July 23, 2019 Filed Jul 25, 2019 22:46 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option (Right to buy) · Derivative | 18,333 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001745285-19-000007 · primary_doc.xml · derivative · entry 1 Kearns Evan · CIK 0001745285 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,333 Underlying: Common Stock · 18,333 shares Expires 2029-07-23 F1 · derivative.exercise_date: Stock option awarded in accordance with Agenus Inc. 2019 Equity Incentive Plan and is eligible to vest, if at all, in a single installment on June 30, 2022 based upon the Company stock price performance. Amount shown reflects the target award. The ultimate award size can range between 0% and 150% of target based on the actual average stock price achieved at the end of the performance period. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 21:27 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option(right to buy) · Derivative | 200,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000899243-19-017832 · doc4.xml · derivative · entry 1 Kearns Evan · CIK 0001745285 · V.P. and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-01-01 F1 · derivative.exercise_date: Option was granted on January 1, 2019, subject to shareholder approval of the Company's 2019 Equity Incentive Plan, which was obtained at the Company's annual shareholder meeting on June 19,2019. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan. Option vests over a three year period, with 1/3 of Option vesting on January 1, 2020, and the balance vesting in equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.